Alkem a compelling long-term investment case due to its strong domestic franchise, improving profitability, and growing international presence.

$ALKEM The company has established itself as one of India's leading pharmaceutical manufacturers, with a diversified portfolio across acute and chronic therapies. Its trusted brands, extensive distribution network, and consistent market share gains provide a solid foundation for sustainable growth. One of the key positives is the increasing contribution from chronic therapies such as cardiology, diabetes, and neurology, which generally deliver higher margins and recurring demand. Alkem is also expanding its specialty portfolio while continuing to strengthen its position in the Indian pharmaceutical market, where healthcare awareness and medicine consumption continue to rise. The company's US business, although historically volatile due to pricing pressure and competition, offers meaningful upside through new product launches and a richer product mix. At the same time, growth in emerging markets provides geographical diversification and reduces dependence on any single region. Financially, Alkem maintains a healthy balance sheet with strong cash generation, disciplined capital allocation, and improving return ratios. Investments in manufacturing capacity, R&D, and product development position the company well for future opportunities while maintaining regulatory compliance. Another positive factor is the structural tailwind for the Indian pharmaceutical sector, driven by an ageing population, increasing health insurance penetration, rising incomes, and government initiatives to improve healthcare access. As one of the established players, Alkem is well placed to benefit from these long-term trends. While risks such as US pricing pressure, regulatory inspections, and raw material cost fluctuations remain, the company's diversified business model and execution track record help mitigate these challenges.